Anzeige
Mehr »
Login
Dienstag, 23.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Breaking News: InnoCan startet in eine neue Ära – FDA Zulassung!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
245 Leser
Artikel bewerten:
(0)

IMPORTANT EQUITY ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Amyris, Inc. and Reminds Investors with Losses to Contact the Firm

IRVINE, CA / ACCESSWIRE / May 22, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against Amyris, Inc. ("Amyris" or the "Company") (Nasdaq: AMRS). Investors who purchased or otherwise acquired shares between March 2, 2017 and April 17, 2017 inclusive (the "Class Period"), are encouraged to contact the Firm before the June 19, 2017 lead plaintiff motion deadline.

If you purchased shares of Amyris during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone at (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the Complaint, throughout the Class Period, Amyris made false and/or misleading statements and/or failed to disclose: that in the first quarter of 2017, the Company made a decision to take an equity stake in one of Blue California's affiliates that focused on the sweetener market instead of cash payment under the license agreement; that due to this decision Amyris would be unable to recognize $10 million in fourth quarter and fiscal year 2016 revenue from the license agreement with Blue California; and that as a result of the above, the Company's public statements were materially false and misleading at all relevant times. When this information came out, Amyris' stock price dropped materially, which caused investors harm according to the Complaint.

If you wish to learn more about this lawsuit, or if you have questions about this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contact

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2017 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.